CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner

Xie,Songping; Tu,Zhenbo; Xiong,Jie; Kang,Ganjun; Zhao,Lina; Hu,Weidong; Tan,Haiyan; Tembo,Kingsley Miyanda; Ding,Qianshan; Deng,Xinzhou; Huang,Jie; Zhang,Qiuping

doi:10.3892/or.2016.5289

CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner

Authors:
- Songping Xie
- Zhenbo Tu
- Jie Xiong
- Ganjun Kang
- Lina Zhao
- Weidong Hu
- Haiyan Tan
- Kingsley Miyanda Tembo
- Qianshan Ding
- Xinzhou Deng
- Jie Huang
- Qiuping Zhang
View Affiliations

Affiliations: Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Immunology, School of Basic Medical Science, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Thoracic Oncology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: December 2, 2016 https://doi.org/10.3892/or.2016.5289
Pages: 921-928

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemoresistance is the main cause of treatment failure and high mortality in advanced lung cancer. Cisplatin, an important chemotherapeutic agent for lung cancer, has been observed to show enormously reduced chemotherapeutic efficacy owing to the development of chemoresistance. CXCR4, a stromal-derived-factor-1 specific chemokine receptor, is highly expressed in non-small cell lung cancer (NSCLC) tissues and participates in cancer progression by regulating cell growth, apoptosis or invasion. In this study, we therefore investigated whether CXCR4 plays a role in the cisplatin associated resistance in NSCLC. We detected the expression of CXCR4 in tissue specimens from 64 NSCLC patients by immunohistochemistry. Cisplatin-resistant NSCLC cells A549/DDP and its parental A549 cells were employed in this study. RNA interference was performed to silence the CXCR4. The influence of CXCR4 on tumor cell chemoresistance, apoptosis and growth, as well as the relationship between CXCR4 and the expression of cytochrome p450 associated molecule CYP1B1 in NSCLC were evaluated. Finally, we found CXCR4 was significantly highly expressed in cisplatin-resistant NSCLC patients and the A549/DDP cell line. CXCR4 inhibition by siRNA reversed chemoresistance and decreased tumor cell proliferation. Bioinformatics analysis showed that the expression of CYP1B1 had a positive correlation with CXCR4, the CYP1B1 silencing significantly decreased CXCR4 expression levels and cisplatin resistance. Immunohistochemistry also verified that CYP1B1 was upregulated in NSCLC tissues of cisplatin-resistant patients. In conclusion, our results indicate that overexpression of CXCR4 in NSCLC promotes cisplatin resistance via CXCR4-mediated CYP1B1 upregulation. Thus, it can be used as a potential therapeutic target in NSCLC chemoresistance patients and be used as a clinical predictor of cisplatin response.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
4	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
5	Teicher BA and Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931. 2010. View Article : Google Scholar : PubMed/NCBI
6	Dai X, Mao Z, Huang J, Xie S and Zhang H: The CXCL12/CXCR4 autocrine loop increases the metastatic potential of non-small cell lung cancer in vitro. Oncol Lett. 5:277–282. 2013.PubMed/NCBI
7	Xie S, Zeng W, Fan G, Huang J, Kang G, Geng Q, Cheng B, Wang W and Dong P: Effect of CXCL12/CXCR4 on increasing the metastatic potential of non-small cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression. Oncol Lett. 7:941–947. 2014.PubMed/NCBI
8	Wang T, Mi Y, Pian L, Gao P, Xu H, Zheng Y and Xuan X: RNAi targeting CXCR4 inhibits proliferation and invasion of esophageal carcinoma cells. Diagn Pathol. 8:1042013. View Article : Google Scholar : PubMed/NCBI
9	Nikzaban M, Hakhamaneshi MS, Fakhari S, Sheikhesmaili F, Roshani D, Ahsan B, Kamali F and Jalili A: The chemokine receptor CXCR4 is associated with the staging of gastric cancer. Adv Biomed Res. 3:162014. View Article : Google Scholar : PubMed/NCBI
10	Teng F, Tian WY, Wang YM, Zhang YF, Guo F, Zhao J, Gao C and Xue FX: Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol. 9:82016. View Article : Google Scholar : PubMed/NCBI
11	Kishima M Okuyama, de Oliveira CE, Banin-Hirata BK, Losi-Guembarovski R, Brajão de Oliveira K, Amarante MK and Watanabe MA: Immunohistochemical expression of CXCR4 on breast cancer and its clinical significance. Anal Cell Pathol (Amst). 2015:8910202015.PubMed/NCBI
12	Nakamura T, Shinriki S, Jono H, Guo J, Ueda M, Hayashi M, Yamashita S, Zijlstra A, Nakayama H, Hiraki A, et al: Intrinsic TGF-β2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells. Oncotarget. 6:1008–1019. 2015. View Article : Google Scholar : PubMed/NCBI
13	Li J, Jiang K, Qiu X, Li M, Hao Q, Wei L, Zhang W, Chen B and Xin X: Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer. BMB Rep. 47:33–38. 2014. View Article : Google Scholar : PubMed/NCBI
14	Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 5:186ra66. 2013. View Article : Google Scholar : PubMed/NCBI
15	Sato M, Larsen JE, Lee W, Sun H, Shames DS, Dalvi MP, Ramirez RD, Tang H, DiMaio JM, Gao B, et al: Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res. 11:638–650. 2013. View Article : Google Scholar : PubMed/NCBI
16	Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson MB, Simon G, Wang J, Coombes KR, Lee JJ, et al: VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 20:3849–3861. 2014. View Article : Google Scholar : PubMed/NCBI
17	Chang I, Mitsui Y, Fukuhara S, Gill A, Wong DK, Yamamura S, Shahryari V, Tabatabai ZL, Dahiya R, Shin DM, et al: Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. Oncotarget. 6:7774–7787. 2015. View Article : Google Scholar : PubMed/NCBI
18	Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH and Schinkel AH: P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int J Cancer. 132:2439–2447. 2013. View Article : Google Scholar : PubMed/NCBI
19	Kudo T, Ozaki Y, Kusano T, Hotta E, Oya Y, Komatsu S, Goda H and Ito K: Effect of buffer conditions on CYP2C8-mediated paclitaxel 6alpha-hydroxylation and CYP3A4-mediated triazolam alpha- and 4-hydroxylation by human liver microsomes. Xenobiotica. 46:241–246. 2016. View Article : Google Scholar : PubMed/NCBI
20	Laroche-Clary A, Le Morvan V, Yamori T and Robert J: Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: Studies with in vitro models. Mol Cancer Ther. 9:3315–3321. 2010. View Article : Google Scholar : PubMed/NCBI
21	Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, et al: Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in castration-resistant prostate cancer (CRPC) patients. BMC Cancer. 10:5112010. View Article : Google Scholar : PubMed/NCBI
22	Vasile E, Tibaldi C, Leon GL, D'Incecco A and Giovannetti E: Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients. J Cancer Res Clin Oncol. 141:1189–1194. 2015. View Article : Google Scholar : PubMed/NCBI
23	Wen CJ, Wu LX, Fu LJ, Shen DY, Zhang X, Zhang YW, Yu J and Zhou HH: Preferential induction of CYP1A1 over CYP1B1 in human breast cancer MCF-7 cells after exposure to berberine. Asian Pac J Cancer Prev. 15:495–499. 2014. View Article : Google Scholar : PubMed/NCBI
24	Xu X, Zhang XA and Wang DW: The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev. 63:597–609. 2011. View Article : Google Scholar : PubMed/NCBI
25	Zhu Z, Mu Y, Qi C, Wang J, Xi G, Guo J, Mi R and Zhao F: CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro. Int J Mol Med. 35:340–348. 2015.PubMed/NCBI
26	Chen Z, Teo AE and McCarty N: ROS-induced CXCR4 signaling regulates mantle cell lymphoma (MCL) cell survival and drug resistance in the bone marrow microenvironment via autophagy. Clin Cancer Res. 22:187–199. 2016. View Article : Google Scholar : PubMed/NCBI
27	Wang Y, Miao H, Li W, Yao J, Sun Y, Li Z, Zhao L and Guo Q: CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells. Biochem Pharmacol. 90:212–225. 2014. View Article : Google Scholar : PubMed/NCBI
28	De Luca A, D'Alessio A, Gallo M, Maiello MR, Bode AM and Normanno N: Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. Cell Cycle. 13:148–156. 2014. View Article : Google Scholar : PubMed/NCBI
29	Wang M, Chen GY, Song HT, Hong X, Yang ZY and Sui GJ: Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer. Exp Ther Med. 2:517–522. 2011.PubMed/NCBI
30	Al Zobair AA, Al Obeidy BF, Yang L, Yang C, Hui Y, Yu H, Zheng F, Yang G, Xie C, Zhou F, et al: Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer. Oncol Rep. 29:1524–1532. 2013.PubMed/NCBI
31	Sison EA, Magoon D, Li L, Annesley CE, Rau RE, Small D and Brown P: Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: Efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget. 5:8947–8958. 2014. View Article : Google Scholar : PubMed/NCBI
32	Sankhwar M, Sankhwar SN, Abhishek A, Gupta N and Rajender S: CYP1B1 gene polymorphisms correlate with an increased risk of urinary bladder cancer in India. Urol Oncol. 34:167. e161–168. 2016. View Article : Google Scholar
33	Yu PJ, Chen WG, Feng QL, Chen W, Jiang MJ and Li ZQ: Association between CYP1B1 gene polymorphisms and risk factors and susceptibility to laryngeal cancer. Med Sci Monit. 21:239–245. 2015. View Article : Google Scholar : PubMed/NCBI
34	Patel SA, Bhambra U, Charalambous MP, David RM, Edwards RJ, Lightfoot T, Boobis AR and Gooderham NJ: Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3. Br J Cancer. 111:2287–2296. 2014. View Article : Google Scholar : PubMed/NCBI